The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The following is a summary of “Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge,” published in the March ...

Abbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business environment continues to be challenging globally. The stock carries a Zacks Rank ...

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

Mumbai: Several Type 1 diabetes patients in India are upset with discontinuation of a continuous glucose monitoring (CGM) sensor that has been the "mo.

Continuous Glucose Monitoring market poised for significant growth, driven by advancements in diabetes management and rising global prevalence.

A study from the University of Bath, published in The American Journal of Clinical Nutrition, found that CGMs often ...

The finding is significant because people can use CGM data to make dietary and lifestyle changes, which may be unnecessary, and the erroneously high readings (indicating glycaemia) could lead them to ...

Experts then compared the blood sugar reading provided by the CGM to the actual levels recorded by the blood tests. They found the CGMs they tested, the Abbot Freestyle Libre 2, bumped up blood ...

The research measured blood sugar responses in healthy volunteers (non-diabetic, within a healthy BMI range) using two methods: a CGM (the Abbot Freestyle Libre 2, a commercially available device ...